Changes in Beneficial Ownership · 4
Moleculin Biotech, Inc.
MBRXNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
rdgdoc.xml
Filing details
- Report period
- 2026-10-15
- Issuer
- Moleculin Biotech, Inc.
- Issuer CIK
- 0001659617
- Trading symbol
- MBRX
Reporting owner 1
- Name
- Foster Jonathan P.
- Reporting owner CIK
- 0001545414
- Relationship
- Officer
- Officer title
- Chief Financial Officer
- Address
- C/O MOLECULIN BIOTECH, INC., 5300 MEMORIAL DR., SUITE 950, HOUSTON, TX, 77007
Non-derivative transactions
| Security | Transaction date | Code | Amount | A / D | Price (USD) | Owned after | Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | 2026-10-15 | M · Form 4 | 130,000 | A | [F1] | 435,673 | D |
| Common Stock | 2026-10-15 | F · Form 4 | 30,485[F2] | D | 0.3701 | 405,188 | D |
Table key
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
- A
- Acquired
- D
- Direct
- F · Form 4
- Securities delivered or withheld for exercise price or tax liability under Rule 16b-3
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy) | 0.3701 | 2026-10-15 | A · Form 4 | 260,000 | A | [F4] | [F3] | 2036-10-15 | Common Stock | 260,000 | 1,287,717 | D |
| Restricted Stock Units | [F5] | 2026-10-15 | A · Form 4 | 260,000 | A | [F4] | [F3] | [F5] | Common Stock | 260,000 | 1,547,717 | D |
| Restricted Stock Units | [F1] | 2026-10-15 | M · Form 4 | 130,000 | D | 0 | [F3] | [F5] | Common Stock | 130,000 | 1,417,717 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
- M · Form 4
- Exempt derivative exercise or conversion under Rule 16b-3
Footnotes
Signature 1
- Signed
- /s/ Jonathan P. Foster
- Date
- 2026-10-16
Company context
We are a late-stage pharmaceutical development company currently evaluating Annamycin, also known as L-Annamycin and by its generic name “naxtarubicin”, which we believe is a “next-generation” anthracycline and, with it, are conducting a pivotal Phase 2/3 trial in combination with cytarabine for the treatment of subjects with relapsed/refractory (R/R) acute myeloid leukemia (AML). We call this the “MIRACLE” trial (derived from Moleculin R/R AML AnnAraC Clinical Evaluation). A blinded preliminary data readout has been released for the MIRACLE trial, we released an interim unblinding of data in June 2026, and we expect an additional unblinding at the end of 2026, thereby concluding Part A of the two-part trial. We believe such early visibility for a pivotal registration-enabling trial is unique in that stakeholders will receive preliminary safety and efficacy data long before the conclusion of the trial.